Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2026)

Xeris Biopharma Holdings' Interest Expenses history runs 7 years deep, the most recent figure standing at $8.6 million for Q1 2026.

• Quarterly Interest Expenses changed 0.0% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $43.2 million, down 78.3% from the prior year.
• Interest Expenses was $8.6 million for Q1 2026 at Xeris Biopharma Holdings, up from $5.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $77.8 million in Q2 2022 and bottomed at $4.4 million in Q4 2022.
• A 5-year average of $13.6 million and a median of $8.6 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses jumped 4221.39% — and 2023, when it plunged 88.89%.
• Xeris Biopharma Holdings' Interest Expenses stood at $4.4 million in 2022, then soared by 85.37% to $8.1 million in 2023, then fell by 25.6% to $6.0 million in 2024, then dropped by 13.33% to $5.2 million in 2025, then soared by 65.57% to $8.6 million in 2026.
• Business Quant data shows XERS's Interest Expenses at $8.6 million in Q1 2026, $5.2 million in Q4 2025, and $8.6 million in Q3 2025.